Oct. 23, 2012
/PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced today that two of its leading Digital Pathology scientists will present the latest advancements in digital pathology multiplexing and algorithm assisted breast cancer testing at the Pathology Visions Conference in
– 31, 2012.
To view the multimedia assets associated with this release, please click
project lead for Ventana Multiplex and Molecular Assays, will present the key concepts of multiplexing gene and protein targets in tissue and discuss the importance and current challenges of translating this technology to the clinical setting. Multiplexing genomic and proteomic targets in Formalin-fixed, Paraffin-embedded (FFPE) tissue is widely regarded as a key enabling technology in the future of personalized medicine and companion diagnostics.
Dr. Gerardo Fernandez
, Medical Director for Digital Pathology at Ventana will discuss the evolution of automated algorithmic analysis of the standard breast cancer immunohistochemistry (IHC) panel, from the pitfalls of early scoring techniques to the more robust late generation methods in use today
"Ventana is committed to Digital Pathology and leads the industry with robust image analysis solutions for clinical applications,"
, PhD, Lifecycle Leader for Digital Pathology and Workflow at Ventana.
In addition to sharing the latest advancements in digital pathology, Ventana will also present the latest versions of its
digital pathology image and workflow management software and
workflow solution for histology lab specimen tracking at Pathology Visions 2012.
With Virtuoso 5.3, a web-based software, Ventana has expanded the user interface to 21 languages, making it easy for international customers to adopt this new technology. The software orchestrates the digital slide workflow from the moment the slide is scanned until the slide image is viewed and the case results reported.